The weekly litigation news digest is live. Subscribe now

IP Verse

Crystalline Forms Of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine And Methods Of Making - EP3856341

The patent EP3856341 was granted to Blueprint Medicines on Sep 6, 2023. The application was filed on Apr 10, 2020 under application number EP20722936A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3856341

BLUEPRINT MEDICINES
Application Number
EP20722936A
Filing Date
Apr 10, 2020
Status
Granted And Under Opposition
Aug 4, 2023
Publication Date
Sep 6, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBJun 5, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2014039714
DESCRIPTIONWO2014100620
DESCRIPTIONWO2015057873
INTERNATIONAL-SEARCH-REPORTWO2015057873
OPPOSITIONWO2015057873
OPPOSITIONWO2021004895

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents